Refining critical structure contouring in STereotactic Arrhythmia Radioablation (STAR): Benchmark results and consensus guidelines from the STOPSTORM.eu consortium.

Cardiac substructures Contouring benchmark Organs at risk (OAR) STereotactic Arrhythmia Radioablation (STAR) Stereotactic Body Radiotherapy (SBRT) Ventricular tachycardia (VT)

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
12 2023
Historique:
received: 16 05 2023
revised: 05 09 2023
accepted: 09 10 2023
medline: 28 11 2023
pubmed: 13 10 2023
entrez: 12 10 2023
Statut: ppublish

Résumé

In patients with recurrent ventricular tachycardia (VT), STereotactic Arrhythmia Radioablation (STAR) shows promising results. The STOPSTORM.eu consortium was established to investigate and harmonise STAR treatment in Europe. The primary goals of this benchmark study were to standardise contouring of organs at risk (OAR) for STAR, including detailed substructures of the heart, and accredit each participating centre. Centres within the STOPSTORM.eu consortium were asked to delineate 31 OAR in three STAR cases. Delineation was reviewed by the consortium expert panel and after a dedicated workshop feedback and accreditation was provided to all participants. Further quantitative analysis was performed by calculating DICE similarity coefficients (DSC), median distance to agreement (MDA), and 95th percentile distance to agreement (HD95). Twenty centres participated in this study. Based on DSC, MDA and HD95, the delineations of well-known OAR in radiotherapy were similar, such as lungs (median DSC = 0.96, median MDA = 0.1 mm and median HD95 = 1.1 mm) and aorta (median DSC = 0.90, median MDA = 0.1 mm and median HD95 = 1.5 mm). Some centres did not include the gastro-oesophageal junction, leading to differences in stomach and oesophagus delineations. For cardiac substructures, such as chambers (median DSC = 0.83, median MDA = 0.2 mm and median HD95 = 0.5 mm), valves (median DSC = 0.16, median MDA = 4.6 mm and median HD95 = 16.0 mm), coronary arteries (median DSC = 0.4, median MDA = 0.7 mm and median HD95 = 8.3 mm) and the sinoatrial and atrioventricular nodes (median DSC = 0.29, median MDA = 4.4 mm and median HD95 = 11.4 mm), deviations between centres occurred more frequently. After the dedicated workshop all centres were accredited and contouring consensus guidelines for STAR were established. This STOPSTORM multi-centre critical structure contouring benchmark study showed high agreement for standard radiotherapy OAR. However, for cardiac substructures larger disagreement in contouring occurred, which may have significant impact on STAR treatment planning and dosimetry evaluation. To standardize OAR contouring, consensus guidelines for critical structure contouring in STAR were established.

Sections du résumé

BACKGROUND AND PURPOSE
In patients with recurrent ventricular tachycardia (VT), STereotactic Arrhythmia Radioablation (STAR) shows promising results. The STOPSTORM.eu consortium was established to investigate and harmonise STAR treatment in Europe. The primary goals of this benchmark study were to standardise contouring of organs at risk (OAR) for STAR, including detailed substructures of the heart, and accredit each participating centre.
MATERIALS AND METHODS
Centres within the STOPSTORM.eu consortium were asked to delineate 31 OAR in three STAR cases. Delineation was reviewed by the consortium expert panel and after a dedicated workshop feedback and accreditation was provided to all participants. Further quantitative analysis was performed by calculating DICE similarity coefficients (DSC), median distance to agreement (MDA), and 95th percentile distance to agreement (HD95).
RESULTS
Twenty centres participated in this study. Based on DSC, MDA and HD95, the delineations of well-known OAR in radiotherapy were similar, such as lungs (median DSC = 0.96, median MDA = 0.1 mm and median HD95 = 1.1 mm) and aorta (median DSC = 0.90, median MDA = 0.1 mm and median HD95 = 1.5 mm). Some centres did not include the gastro-oesophageal junction, leading to differences in stomach and oesophagus delineations. For cardiac substructures, such as chambers (median DSC = 0.83, median MDA = 0.2 mm and median HD95 = 0.5 mm), valves (median DSC = 0.16, median MDA = 4.6 mm and median HD95 = 16.0 mm), coronary arteries (median DSC = 0.4, median MDA = 0.7 mm and median HD95 = 8.3 mm) and the sinoatrial and atrioventricular nodes (median DSC = 0.29, median MDA = 4.4 mm and median HD95 = 11.4 mm), deviations between centres occurred more frequently. After the dedicated workshop all centres were accredited and contouring consensus guidelines for STAR were established.
CONCLUSION
This STOPSTORM multi-centre critical structure contouring benchmark study showed high agreement for standard radiotherapy OAR. However, for cardiac substructures larger disagreement in contouring occurred, which may have significant impact on STAR treatment planning and dosimetry evaluation. To standardize OAR contouring, consensus guidelines for critical structure contouring in STAR were established.

Identifiants

pubmed: 37827279
pii: S0167-8140(23)89843-7
doi: 10.1016/j.radonc.2023.109949
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109949

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Brian V Balgobind (BV)

Department of Radiation Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands. Electronic address: b.v.balgobind@amsterdamumc.nl.

Jorrit Visser (J)

Department of Radiation Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.

Melanie Grehn (M)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Marianne Marquard Knap (M)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Dirk de Ruysscher (D)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University, Maastricht, the Netherlands.

Mario Levis (M)

Department of Oncology, University of Torino, Torino, Italy.

Pino Alcantara (P)

Department of Radiation Oncology, Hospital Clínico San Carlos, Faculty of Medicine, University Complutense of Madrid, Madrid, Spain.

Judit Boda-Heggemann (J)

Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Marcus Both (M)

Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Salvatore Cozzi (S)

Radiation Oncology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy; Radiation Oncology Department, Centre Léon Bérard, Lyon, France.

Jakub Cvek (J)

Department of Oncology, University Hospital and Faculty of Medicine, Ostrava, Czech Republic.

Edith M T Dieleman (EMT)

Department of Radiation Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.

Olgun Elicin (O)

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Niccolò Giaj-Levra (N)

Department of Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.

Raphaël Jumeau (R)

Department of Radio-Oncology, Lausanne University Hospital, Lausanne, Switzerland.

David Krug (D)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Manuel Algara López (M)

Department of Radiotherapy, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain.

Michael Mayinger (M)

Department of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland.

Felix Mehrhof (F)

Department for Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Marcin Miszczyk (M)

IIIrd Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland.

Maria José Pérez-Calatayud (MJ)

Department of Radiation Oncology, Hospital General Valencia, Valencia, Spain.

Luuk H G van der Pol (LHG)

Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.

Peter-Paul van der Toorn (PP)

Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.

Viviana Vitolo (V)

Radiation Oncology Clinical Department, National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Pieter G Postema (PG)

Department of Cardiology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.

Etienne Pruvot (E)

Heart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Joost C Verhoeff (JC)

Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.

Oliver Blanck (O)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH